Using Antibiotics May Increase Risk of Developing ALS, Swedish Study Suggests
Using antibiotics may increase the risk of developing amyotrophic lateral sclerosis (ALS), with…
Articles by Ana Pena, PhD
Investigational Therapy Tofersen Can Reduce Toxic SOD1 Protein Levels in Familial ALS Patients, Study Shows
Biogen’s investigational therapy tofersen can significantly reduce toxic levels of SOD1 protein and may slow disability progression in people with …
Project ALS and Columbia University Unite in $6.3M Push for ‘Meaningful’ Treatments
Project ALS and Columbia University are launching a new platform…
FDA Reviewing New Drug Application for ALS Therapy Riluzole Oral Strips
Aquestive’s new drug application for Exservan — an investigational oral film of…
MTPA, Massachusetts General Launching Study on Biomarkers of Radicava Response
Mitsubishi Tanabe Pharma America (MTPA), in collaboration with the Massachusetts General Hospital (MGH), is conducting a study to identify…
Patient-derived Cell Model for Use in ALS Research Wins International 3Rs Prize
A model of motor neuron disease based on patient-derived stem cells won the 2018 International 3Rs Prize for its potential to…
Amylyx Completes Patient Recruitment for Phase 2 Study Testing AMX0035 for ALS
Amylyx has completed patient recruitment for the Phase 2 clinical trial CENTAUR, which addresses…
User-friendly Tool May Help Patients and Their Doctors to Evaluate ALS Genetic Risk
Examining the genetic risk for amyotrophic lateral sclerosis (ALS) may become a lot easier with a user-friendly tool called …
High-dose Vitamin B12 May Improve ALS Prognosis if Started Early, Study Suggests
Treatment with ultra-high-dose methylcobalamin, the physiologically active form of vitamin B12, may improve the…
EnClear, Developer of Device to Slow ALS, Spins Out of QurAlis
EnClear Therapies, a biotech company developing a device to halt the progression of neurological diseases…